17 alpha-hydroxylase deficiency differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 24: Line 24:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Karyotyping
|-
|-
![[3 beta-hydroxysteroid dehydrogenase deficiency]]
![[17-alpha-hydroxylase deficiency]]  
|
|
* HSD3B2  [[gene]] [[mutation]]
* [[CYP17A1|CYP17A1 gene mutation]]
|
|
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis.
* Female [[external genitalia]]
* Mild [[virilization]] in 46,XX individuals
 
* [[Primary amenorrhea]]
* [[Hypertension]]
* Absence of secondary [[sexual characteristics]]
* Minimal [[body hair]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Yes in [[female]]
No
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Line 41: Line 45:
Normal
Normal
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]] and [[XX]]
[[XY]]
|-
|-
![[17-alpha-hydroxylase deficiency]]  
![[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
|
* [[CYP17A1|CYP17A1 gene mutation]]
* HSD3B2  [[gene]] [[mutation]]
|
|
* Female [[external genitalia]]
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis
 
* Mild [[virilization]] in 46,XX individuals
* [[Primary amenorrhea]]
* [[Hypertension]]
* Absence of secondary [[sexual characteristics]]
* Minimal [[body hair]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
No
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
No
Yes in [[female]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Line 64: Line 64:
Normal
Normal
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
[[XY]]
[[XY]] and [[XX]]
|-
|-
![[Gonadal dysgenesis]]
![[Gonadal dysgenesis]]
Line 90: Line 90:
* Loss of [[testicular]] function and tissue early in development  
* Loss of [[testicular]] function and tissue early in development  
|
|
* Female phenotype with atrophic [[Mullerian ducts]].
* Female phenotype with atrophic [[Mullerian ducts]]
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
No
No
Line 113: Line 113:
* Laboratory:
* Laboratory:
** Unresponsiveness to [[hCG]]  
** Unresponsiveness to [[hCG]]  
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]).
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]])
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
No
No
Line 135: Line 135:


* Impaired external [[virilization]] during [[embryogenesis]]  
* Impaired external [[virilization]] during [[embryogenesis]]  
* Defective conversion of [[testosterone]] to [[DHT]].
* Defective conversion of [[testosterone]] to [[DHT]]  
* [[Testosterone]]:[[DHT]] ratio is >10:1
* [[Testosterone]]:[[DHT]] ratio is >10:1
| align="center" style="padding: 5px 5px; background: " |
| align="center" style="padding: 5px 5px; background: " |
Line 210: Line 210:
* Functional, sellar masses
* Functional, sellar masses
|
|
* Normal [[female genitalia]],
* Normal [[female genitalia]]


* Delayed [[puberty]]
* Delayed [[puberty]]
Line 317: Line 317:
! Gestational [[hyperandrogenism]]
! Gestational [[hyperandrogenism]]
| colspan="2" |
| colspan="2" |
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high
* High maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]])  
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]]
* If [[virilization]] is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic [[steroid]] not measured in assays for [[testosterone]] or other [[androgens]]
|
|
Line 395: Line 395:
![[Cushing’s syndrome]]
![[Cushing’s syndrome]]
|
|
* The main pathogenetic mechanism is linked to the excess
* Excess [[cortisol]] which saturates 11-HSD2 activity
of [[cortisol]] which saturates 11-HSD2 activity,
* Allows [[cortisol]] to bind [[mineralocorticoid receptor]]
* This allows [[cortisol]] to bind [[mineralocorticoid receptor]]
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
|Rapid [[Obesity|weight gain]], particularly of the [[trunk]] and [[face]] with [[limbs]] sparing ([[central obesity]])
* Proximal [[muscle weakness]]
* Proximal [[muscle weakness]]
* A [[round face]] often referred to as a "[[moon face]]"
* A [[round face]] often referred to as a[[moon face|"moon face]]"
* Excess [[sweating]]
* Excess [[sweating]]
* [[Headache]]
* [[Headache]]
Line 461: Line 460:


* Normal renal function
* Normal renal function
|No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule
|No excess [[mineralocorticoid]]; an increased activity of the [[thiazide]]-sensitive Na–Cl co-transporter in the [[distal tubule]]
|↓
|↓
|Normal
|Normal
|Hyperkalemia
|[[Hyperkalemia]]
|thiazide diuretics and/or dietary sodium restriction
|Thiazide diuretics and/or dietary sodium restriction
|-
|-
| rowspan="4" |Exogenous causes
| rowspan="4" |Exogenous causes
Line 489: Line 488:
|↓
|↓
|↓
|↓
|Urinary free cortisol Moderate ↑
|Moderate ↑ in urinary free cortisol  
|Discontinue licorice
|Discontinue licorice
|-
|-
!Grapefruit
!Grapefruit
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD (11β-Hydroxysteroid dehydrogenase)
|
|
* [[Hypertension]]
* [[Hypertension]]
Line 504: Line 503:
![[Estrogens]]
![[Estrogens]]
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]
* Increased [[blood pressure]] values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing [[secondary hyperaldosteronism]] due to the stimulation of the synthesis of [[angiotensinogen]]
|
|
* [[Hypertension]]
* [[Hypertension]]

Revision as of 13:44, 3 October 2017

Congenital adrenal hyperplasia main page

17 alpha-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 17 alpha-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

17 alpha-hydroxylase deficiency differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 17 alpha-hydroxylase deficiency differential diagnosis

CDC on 17 alpha-hydroxylase deficiency differential diagnosis

17 alpha-hydroxylase deficiency differential diagnosis in the news

Blogs on 17 alpha-hydroxylase deficiency differential diagnosis

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency

Risk calculators and risk factors for 17 alpha-hydroxylase deficiency differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea and female external genitalia. Some of these causes include Pregnancy, androgen insensitivity syndrome, 3beta-hydroxysteroid dehydrogenase type 2 deficiency, 17-alpha-hydroxylase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.

Differentiating 17 alpha-hydroxylase deficiency from other Diseases

17 alpha-hydroxylase deficiency must be differentiated from diseases with primary amenorrhea. Some of these causes include androgen insensitivity syndrome, 3 beta-hydroxysteroid dehydrogenase deficiency, gonadal dysgenesis, testicular regression syndrome, LH receptor defects, 5-alpha-reductase type 2 deficiency, mullerian agenesis, primary ovarian insufficiency, hypogonadotropic hypogonadism and turner syndrome.[1][2][3][4][5][6][7][8]

Differential diagnosis for primary amenorrhea:

Disease name Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
17-alpha-hydroxylase deficiency

No

No

Normal

Normal

XY

3 beta-hydroxysteroid dehydrogenase deficiency

Yes in female

Yes in female

Normal

Normal

XY and XX

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

XY

LH receptor defects

No

No

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY

Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

45 XO

17 alpha-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[9][10]

Disease name Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

17 alpha-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):

Pseudohyperaldosteronism causes Disease Etiology Clinical features Labratory Treatment
Elevated mineralocorticoid Renin Aldosterone Other
Endogenous causes 17 alpha-hydroxylase deficiency Mutations in the CYP17A1 gene Deoxycorticosterone (DOC) Cortisol Corticosteroids
11β-hydroxylase deficiency Mutations in the CYP11B1 gene Cortisol
Apparent mineralocorticoid excess syndrome (AME) Genetic or acquired defect of 11-HSD gene Cortisol has mineralocorticoid effects Urinary free cortisone ↓↓ Dexamethasone and/or mineralocorticoid blockers
Liddle’s syndrome (Pseudohyperaldosteronism type 1) Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism Cortisol Amiloride or triamterene
Cushing’s syndrome Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity) Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑
  • Adrenalectomy
Insensitivity to glucocorticoids (Chrousos syndrome) Mutations in glucocorticoid receptor (GR) gene Deoxycorticosterone (DOC) Cortisol Dexamethasone
Cortisol-secreting adrenocortical carcinoma Multifactorial

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)

Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑ Surgery
Geller’s syndrome Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR Severe hypertension particularly during pregnancy Progesterone has mineralocorticoid effects - mineralocorticoid blockers
Gordon’s syndrome (Pseudohypoaldosteronism type 2) Mutations of at least four genes have been identified, including WNK1 and WNK4
  • Normal renal function
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule Normal Hyperkalemia Thiazide diuretics and/or dietary sodium restriction
Exogenous causes Corticosteroids with mineralocorticoid activity Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone, Medications such as fludrocortisone - Change the treatment
Licorice ingestion Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone - Moderate ↑ in urinary free cortisol Discontinue licorice
Grapefruit High assumption of naringenin, a component of grapefruit, can also block 11-HSD (11β-Hydroxysteroid dehydrogenase) - - Discontinue grapefruit
Estrogens Estrogens can retain sodium and water by different mechanisms, causing: - - Discontinue estrogens

References

  1. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  2. Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  3. Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  4. Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  5. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  6. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  7. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  8. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.
  9. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  10. White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.